2021
DOI: 10.1158/1078-0432.ccr-20-4298
|View full text |Cite
|
Sign up to set email alerts
|

Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study

Abstract: Lutetium-177-PSMA-617 in low-volume hormone sensitive metastatic prostate cancer, a prospective pilot study.

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
44
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 68 publications
(59 citation statements)
references
References 37 publications
4
44
0
Order By: Relevance
“…In PSMA therapy, the kidneys are considered the main OAR, but the salivary glands should not be neglected either [35,36], whereas other organs such as the spleen and liver may not be considered as OAR. In contrast to previously published dosimetry data [37], lacrimal glands are not considered as OAR in clinical routine, also confirmed by recently published data [38].…”
Section: Introductionsupporting
confidence: 68%
“…In PSMA therapy, the kidneys are considered the main OAR, but the salivary glands should not be neglected either [35,36], whereas other organs such as the spleen and liver may not be considered as OAR. In contrast to previously published dosimetry data [37], lacrimal glands are not considered as OAR in clinical routine, also confirmed by recently published data [38].…”
Section: Introductionsupporting
confidence: 68%
“…However, the TheraP trial required an FDG-PET to exclude patients with metabolically active, probably low-differentiated disease sites lacking PSMA expression; patients' outcomes, not surprisingly, appeared superior to those reported in the VISION study and might serve as a further argument for further optimizing the eligibility screening. Of note, Lu-PSMA is also being prospectively evaluated as metastasis-directed therapy after surgery and external beam radiotherapy in patients with low-volume mHSPC [70].…”
Section: The Advent Of Lutetium-177-psma-617mentioning
confidence: 99%
“…Ongoing trials are investigating the early use of PRLT in the treatment sequence for patients with progressing metastatic prostate cancer. A pilot study reported on the use of PRLT as an L1 treatment for patients with metastatic low-volume hormone-sensitive prostate cancer [51]. The findings motivated the hospital to commence two RCTs (NCT03828838 and NCT04443062, ClinicalTrials.gov, accessed on 30 June 2021).…”
Section: Discussionmentioning
confidence: 99%